Rapport Therapeutics, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Rapport Therapeutics issued 8.33M common shares at $21/share (~$175M gross) plus pre-funded warrants, alongside a concurrent private placement of 1.43M shares at $21/share (~$30M), and a separate $150M convertible notes offering (2.25% due 2032, convertible at $26.78/share). Underwriters: Morgan Stanley, Leerink Partners, Evercore. Total capital raised: approximately $365M (before underwriting fees). Proceeds designated for RAP-219 clinical trials, R&D, and operations through end of 2029.
Why this rating
Substantial capital raise (~$365M) is ~132% of market cap, materially strengthening cash runway. However, significant dilution from ~9.76M new shares (post-warrant exercise) plus convertible conversion headroom (~5.6M shares at conversion cap). For early-stage biotech, this is material financing but not transformational; clinical trial success/failure is more pivotal.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.